Skip to main content
Clinical Trials/JPRN-jRCT2080220921
JPRN-jRCT2080220921
Unknown
Phase 1

A Phase I, Open-label, Multiple-dose, Dose-escalation Study To Assess the Safety and Tolerability of AZD8931 Monotherapy in Japanese Patients With Advanced Solid Malignancies and in Combination With Paclitaxel in Japanese Female Patients With Advanced Breast Cancer

AstraZeneca0 sitesNovember 19, 2009

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
AstraZeneca
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 19, 2009
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Cancer that is refractory to standard therapies, or for which no standard therapies exist (monotherapy part)
  • \-Patients suitable for Paclitaxel chemotherapy, who are not candidates for hormonal and anthracycline therapy (combination part)
  • \-Life expectancy more than 12 weeks

Exclusion Criteria

  • \-Inadequate kidney, liver, heart, gastric, lung or eye function
  • \-Brain metastases
  • \-Hypersensitive to paclitaxel (combination part)

Outcomes

Primary Outcomes

Not specified

Similar Trials